Featured Suppliers:

Antares Pharma Incorporated

News and Blogs

- News, Search Jobs, Events

www.biospace.com | Nov 11, 2009

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced the simultaneous signing of a license and an asset purchase agreement with Ferring International Center S.A.

http://www.biospace.com/news_story.aspx?StoryID=162448&full=1

News from Zibb.com

Total : 26 View more »

Ferring International to acquire assets of Antares Pharma - Zibb.com

Nov 16, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --

Ferring International Center S.A., a Swiss biopharmaceutical company, has agreed to acquire the research equipment from Antares Pharma, Inc., a US-based pharmaceutical company. Ferring will also assume the responsibility of Antares' leased development facility at Allschwil, Switzerland.

In addition, Ferring has signed an exclusive license agreement with Antares for transdermal gel delivery technology.

Deal Type    Acquisition
Sub-Category Asset Purchase
Deal Status  Announced: 2009-11-11

Deal Participants

Target (Company)   Antares Pharma, Inc. - Assets
Acquirer (Company) Ferring International Center S.A.
Vendor (Company)   Antares Pharma, Inc.

Companies: Antares Pharma, Inc. (AIS)

Permalink

Antares Pharma signs license agreement Ferring International - Zibb.com

Nov 13, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --

Antares Pharma, Inc., a US-based pharmaceutical company, has signed an exclusive license agreement with Ferring International Center S.A., a Switzerland-based biopharmaceutical company.

According to the terms of the agreement, Ferring has obtained rights to certain intellectual property relating to Antares' proprietary transdermal gel delivery technology.

In addition, Ferring has agreed to acquire the research equipment from Antares. Ferring will assume the responsibility of Antares' leased development facility at Allschwil, Switzerland.

Deal Type    Partnership
Sub-Category Acquisition of Rights
Deal Status  Announced: 2009-11-11

Deal Participants

Partner 1 (Company) Antares Pharma, Inc.
Partner 2 (Company) Ferring International Center S.A.

Companies: Antares Pharma, Inc. (AIS)

Permalink

Antares Pharma signs license agreement Ferring International - Zibb.com

Nov 16, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --

Antares Pharma, Inc., a US-based pharmaceutical company, has signed an exclusive license agreement with Ferring International Center S.A., a Switzerland-based biopharmaceutical company.

Under the terms of the agreement, Ferring has obtained rights to certain intellectual property relating to Antares' proprietary transdermal gel delivery technology.

In addition, Ferring has agreed to acquire the research equipment from Antares. Ferring will assume the responsibility of Antares' leased development facility at Allschwil, Switzerland.

Deal Type    Partnership
Sub-Category Acquisition of Rights
Deal Status  Announced: 2009-11-11

Deal Participants

Partner 1 (Company) Antares Pharma, Inc.
Partner 2 (Company) Ferring International Center S.A.

Companies: Antares Pharma, Inc. (AIS)

Permalink

Antares Pharma Inks Licensing and Asset Purchase Pact with Ferring - Zibb.com

Nov 17, 2009 (Close-Up Media via COMTEX) --

Antares Pharma, Inc. has announced the simultaneous signing of a license and an asset purchase agreement with Ferring International Center.

Under the terms of the exclusive license agreement Ferring obtained rights to certain intellectual property relating to Antares' proprietary transdermal gel delivery technology. Upon closing of the asset purchase agreement Ferring will purchase research equipment and assume responsibility for Antares' leased development facility in Allschwil, Switzerland. A majority of the current employees at the facility will become employees of Ferring. Importantly, these agreements will have no impact on Antares' current licenses, the transdermal clinical pipeline, or marketed products including Anturol LibiGel, Nestorone, and Elestrin. Financial terms of the agreements which consist of upfront payments and milestones were not disclosed.

"We are pleased that we have expanded our strong partnership with Ferring to include our transdermal gels and delighted that Ferring has agreed to retain a significant majority of our employees at our Allschwil facility," said Paul K. Wotton, Ph.D., President and Chief Executive Officer.

"We are committed to developing ever more innovative and patient-convenient delivery systems for our compounds and this agreement is another step in our efforts in this direction," said, Dr Pascal Danglas, Ferring's Executive Vice President Clinical & Product Development.

Dr. Wotton continued, "These agreements represent another major step in focusing Antares on our growing parenteral injector business, without losing the potential upside from our marketed and clinical stage transdermal gel programs, while at the same time reducing our overhead costs and burn rate."

Antares Pharma focuses on self-injection delivery technologies and topical gel-based pharmaceutical products.

((Comments on this story may be sent to health@closeupmedia.com))

Companies: Antares Pharma, Inc. (AIS)

Permalink

Web Sites

Total : 84 View more »

Antares Pharma, Inc., Incorporated

San Diego - – Published today by ICON Group International, Ltd. Two of the most comprehensive studies to date on labor productivity and vertical gap analysis benchmarks for Antares Pharma, Inc. (NAS: ANTR).

http://www.icongrouponline.com/pr/Antares_Pharma,_Inc_US/PR.html

Universal Metal L.L.C.

While large runs continue to be Universal Metals' specialty, all orders are completed by fabricating to exact blueprint specifications.

http://www.universalmetal-llc.com/page1.html

Antares Pharma Drug-Delivery Company Profile (market briefing)

Antares has an established, marketed product line of injector systems and transdermal technologies. In addition, the company has the opportunity to blend its injection and gel technologies to create new drug-delivery solutions, promising a broad array of future product opportunities.

http://www.biz-lib.com/ZEB67433.html

Antares Pharma Inc. - Improving Pharmaceuticals Through Advanced Drug Delivery Systems

Jack E. Stover , President & CEO Mr. Stover joined Antares Pharma as President and Chief Operating Officer in July 2004 and was appointed Chief Executive Officer and a member of our Board of Directors in September 2004. Prior to joining Antares Pharma, Mr.

http://www.antarespharma.com/Corporate.htm